Navigation Links
Nanoparticle Breast Cancer Drug Approved by FDA

Research at Northwestern University Feinberg School of Medicine played a significant role in Food and Drug Administration approval of Abraxane (paclitaxel protein-bound particles for injectable suspension), indicated for the treatment of metastatic breast cancer. "The approval means that women with metastatic breast cancer no longer need to endure the toxicities associated with solvents and will no longer need steroid premedication when they receive this albumin-bound form of paclitaxel," said principal clinical study investigator William J. Gradishar, M.D., associate professor of medicine, division of hematology/oncology at Feinberg and co-director, Lynn Sage Breast Cancer Program at Northwestern Memorial Hospital.

Gradishar is also a breast cancer researcher at The Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

"In our research, participants who no longer responded to some of the more common treatments showed improvement with Abraxane and experienced less-severe side effects that made treatment more tolerable," Gradishar said.

Abraxane is engineered using a proprietary process (protein-bound nanoparticle technology) to create tiny particles (nanoparticles 100th the size of a red blood cell) in which the active chemotherapeutic drug, paclitaxel, is bound to a naturally occurring protein called albumin.

By using this nanotechnology, the active component (paclitaxel) can be delivered into the body at a 50 percent higher dose over 30 minutes.

This contrasts with Taxol, in which paclitaxel is dissolved in a toxic solvent, which requires pre-medication with steroids and antihistamines to avoid hypersensitivity reactions and must be given in infusions for up to three hours.

Because Abraxane is solvent-free, solvent-related toxicities are eliminated and premedication is not required.

In the clinical studies, the response rate for all participants treated with Abraxane was almost twice that of
'"/>

Source:Northwestern University


Page: 1 2

Related biology news :

1. DNA Molecules Used To Assemble Nanoparticles
2. Imaging Lymph Nodes with Nanoparticles
3. Taking Aim With Nanoparticle PEBBLEs
4. Probing The Promise And Perils Of Nanoparticles
5. Nanoparticles offer new hope for detection and treatment
6. Nanoparticles carry cancer-killing drugs into tumor cells
7. Nanoparticles, nanoshells, nanotubes: How tiny specks may provide powerful tools against cancer
8. Nanoparticle assembly enters the fast lane
9. Nanoparticles for delivery of prostate cancer treatment
10. Nanoparticles can track cells deep within living organisms
11. Cancer tip -- Nanoparticles can damage DNA, increase cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nanoparticle Breast Cancer Drug Approved FDA

(Date:5/23/2013)... Pacific Northwest National Laboratory honored more than ... of intellectual property at PNNL,s annual Intellectual Property ... The Department of Energy national laboratory named materials ... his work developing battery materials that can store ... electrical grid, and reduce the time it takes ...
(Date:5/23/2013)... 284 million tons of cargo, transit the Panama Canal each ... the Panama Canal Authority. Each time a ship passes through, ... Gatun Lake, which is also a source of water for ... However, the advent of very large "super" cargo ships, now ... demanded change. The Panama Canal is being expanded to create ...
(Date:5/23/2013)... Health at Emory University, along with partners at ... $4 million grant over four years to establish ... Exposome Research Center: Understanding Lifetime Exposures). The grant ... the United States. , The HERCULES Center ... Health Sciences (NIEHS) of the National Institutes of ...
Breaking Biology News(10 mins):PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
... CLEMSON, S.C. The environmental engineering and Earth ... $400,000 faculty-development grant from the U.S. Nuclear Regulatory Commission ... nuclear science. Clemson is one of 16 U.S. ... by the NRC to boost nuclear education and expand ...
... have helped settle a long-standing debate about the origin of ... to a new study by University of British Columbia researchers. ... Proceedings of the National Academy of Sciences Early Edition, ... and its role in definitively linking the evolutionary histories of ...
... a gene widely known for precisely positioning and sculpting ... a finding that could be useful for understanding the ... of children are being born with genital and urinary ... Nature Communications , researchers at the University of ...
Cached Biology News:$400,000 NRC grant to develop nuclear engineering faculty at Clemson 2'Little brown balls' tie malaria and algae to common ancestor: UBC research 2Sluggish cell division may help explain genital defects 2Sluggish cell division may help explain genital defects 3Sluggish cell division may help explain genital defects 4
(Date:5/23/2013)... 2013 Graphite Metallizing Corporation announces ... mounted in stainless steel pillow blocks. This series ... with the application and installation versatility of pillow ... work exceptionally well when submerged in water, ... such as acids, alkalies, hydrocarbons, black liquor, and ...
(Date:5/23/2013)... The maker community is a contemporary group ... focus on learning practical skills while applying them creatively ... their ideas to life via crowdfunding. A subgroup within ... projects using biology. Glowing Plant has worked for months ... glow with bioluminescence genes, and has now pursued crowdfunding ...
(Date:5/23/2013)... Virobay, Inc. today announced that their development ... important milestone, as Virobay has now initiated a Phase ... S inhibitor.   The first Phase 1 ... designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics ... "The initiation of this Phase 1 trial with ...
(Date:5/23/2013)... 23, 2013 Northwest Biotherapeutics (NASDAQ: ... ® personalized immune therapies for solid tumor cancers, ... this year,s American Society Of Clinical Oncology (ASCO) meeting ... leadership role in immune therapy.  (Logo: ... is the pre-eminent conference focused on clinical treatment of ...
Breaking Biology Technology:Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... Group, Inc., a leading provider of clinical development services ... companies, today announced that more than twenty posters will ... Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition ... N. Morial Convention Center in New Orleans, Louisiana. ...
... Reportlinker.com announces that a new market research ... Building Biotech Technology Transfer Opportunities: ... http://www.reportlinker.com/p0185305/Building-Biotech-Technology-Transfer-Opportunities-Sponsor-and-developer-strategies-for-success.html ... to introduce new products in an environment ...
... 4, 2010 PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, announced today that the Company ... the Qualifying Therapeutic Discovery Project, enacted as part of ... (P.L. 111-148). The grant is a benefit targeted to ...
Cached Biology Technology:PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting 2PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting 3Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 2Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 3Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 4Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 5Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 6Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 7PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000 2PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000 3
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
...
Biology Products: